Annual report pursuant to Section 13 and 15(d)

Reverse Merger - Summary of Final Purchase Price Allocation (Detail)

v3.20.1
Reverse Merger - Summary of Final Purchase Price Allocation (Detail) - OncoGenex Pharmaceuticals, Inc [Member]
$ in Thousands
Aug. 01, 2017
USD ($)
Business Acquisition [Line Items]  
Cash, cash equivalents and marketable securities $ 12,376
Prepaid expenses and other assets 518
Intangible assets license agreements 8,610
Accounts payable, accrued expenses and other liabilities (4,054)
Deferred tax liability (2,928)
Contingent value rights (200)
Excess negative goodwill (1,272)
Total purchase price $ 13,050